药物调节生物标志物治疗糖尿病心肌病的研究进展  

Research progress on drugs in treatment of diabetic cardiomyopathy by regulating biomarkers

作　　者：王瑶[1] 胡蕴慧 李晓强 孙磊[3] WANG Yao;HU Yunhui;LI Xiaoqiang;SUN Lei(Department of Endocrinology and Metabolism,Tianjin Hospital,Tianjin 300299,China;Tasly Pharmaceutical Group Co.,Ltd.,Tianjin 300410,China;Department of Cardiology,Tianjin Hospital,Tianjin 300299,China)

机构地区：[1]天津医院内分泌科,天津300299 [2]天士力医药集团股份有限公司,天津300410 [3]天津医院心内科,天津300299

出　　处：《现代药物与临床》2024年第9期2431-2436,共6页Drugs & Clinic

基　　金：天津市卫健委中医、中西医结合科研课题(2023212)。

摘　　要：糖尿病心肌病是一种由糖尿病导致的严重并发症,尚无有效的靶向药物治疗策略。糖尿病心肌病早期生物标志物对糖尿病心肌病的早期诊断、降低其导致的死亡率具有重要的临床意义,对相关药物的研发和药效评价也具有重要的指导意义。总结了传统临床诊断标志物、炎症相关标志物、心肌纤维化相关标志物、心肌重构相关标志物在糖尿病心肌病药物治疗中的应用情况,归纳了调节生物标志物治疗糖尿病心肌病的药物研究进展,期望为相关药物的药效评价提供参考。Diabetic cardiomyopathy is a serious complication caused by diabetes,and there is no effective targeted drug therapy strategy.The early biomarkers of diabetic cardiomyopathy have important clinical significance for the early diagnosis of diabetes cardiomyopathy and the reduction of mortality caused by it,and also have important guiding significance for the development and efficacy evaluation of related drugs.This article summarized the application of traditional clinical diagnostic markers,inflammation related markers,myocardial fibrosis related markers,and myocardial remodeling related markers in the drug treatment of diabetic cardiomyopathy,and summarized the drug research progress of regulating biomarkers in treatment of diabetic cardiomyopathy,hoping to provide reference for the efficacy evaluation of related drugs.

关 键 词：药物 糖尿病心肌病 生物标志物 炎症 心肌纤维化 心肌重构 

分 类 号：R977[医药卫生—药品]